Press Releases Assembly Biosciences, Inc.

Equities

ASMB

US0453962070

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
12.85 ^USD	-2.28%		-0.39%	+30.57%

Mar. 28	Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 19	Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights	Mar. 28	AQ
Assembly Biosciences Announces Effective Date of Reverse Stock Split	Feb. 08	GL
Assembly Biosciences Announces Effective Date of Reverse Stock Split	Feb. 08	AQ
Assembly Biosciences Provides Anticipated Development Milestones for 2024	Jan. 04	GL
Assembly Biosciences Provides Anticipated Development Milestones for 2024	Jan. 04	AQ
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Nov. 10	GL
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Nov. 10	AQ
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®	Nov. 10	GL
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®	Nov. 10	AQ
Assembly Biosciences: Q3 Earnings Snapshot	Nov. 08	AQ
Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates	Nov. 08	GL
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer	Nov. 08	GL
Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer	Nov. 08	AQ
Nano-Cap Stock Momentum Watchlist (SING, MGRX, ICU, ASMB)	23-10-20	AQ
Assembly Biosciences : 737.6 KB	23-10-17	PU
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®	23-10-11	GL
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®	23-10-11	AQ
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor	23-10-02	GL
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor	23-10-02	AQ
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting	23-09-19	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Assembly Biosciences, Inc.

Equities

ASMB

US0453962070

Press Releases

Filters